IBD5 polymorphisms in inflammatory bowel disease: Association with response to infliximab

Table 2 Genotype frequencies of the IBD5 SNPs in NOD2/CARD15-negative Crohn’s disease patients and ethnically-matched controls.

	TT (%)	GT (%)	GG (%)
Controls (n = 511)	170 (33.3)	236 (46.2)	105 (20.5)
CD patients (n = 140)	32 (22.9)	69 (49.3)	39 (27.9)a
CD-L1 (n = 55) terminal ileum + UG	16 (29.1)	25 (45.5)	14 (25.5)
CD-L2 (n = 31) colon	8 (25.8)	15 (48.4)	8 (25.8)
CD-L3 (n = 54) ileocolon	8 (14.8)	29 (53.7)	17 (31.5)b
CD-B1 (n = 65) inflammatory	17 (26.1)	33 (50.8)	15 (23.1)
CD-B2 (n = 15) stricturing	6 (40)	7 (46.7)	2 (13. 3 )
CD-B3 (n = 59) fistulizing	9 (15.25)	28 (47.5)	22 (37.3)d
CD-perianal (n = 34)	6 (17.7)	19 (55.9)	9 (26.5)
CD-non perianal (n = 106)	26 (24.5)	50 (47.2)	30 (28.3)

(GG+GT) vs TT:

^aP<0.05; OR (CI) = 1.68 (1.07-2.66) compared to controls. (GG+GT) vs TT:

^bP<0.01; OR (CI) = 2.87 (1.27-6.73) compared to controls. (GG+GT) vs TT:

^dP<0.01; OR (CI) = 2.77 (1.28-6.2) compared to controls.